Fundraising Reference

---
name: fundraising-reference
description: "Use when checking what moved (a bimodal private venture market, and the US charitable deduction rewritten effective January 2026, verified August 2026), checking a fundraising anti-pattern, correcting a misconception, looking up a benchmark or standard term, finding the canon, or needing a picker and the checklist to run before you sign or accept. Companion to the other fundraising-fundamentals skills."
---

# Fundraising Fundamentals: What Moved, Anti-Patterns, Misconceptions, and Canon

> **Part 6 of 6** of the *Fundraising Fundamentals* reference (plugin `fundraising-fundamentals`), covering §26–§32. Sibling skills: `fundraising-what-it-is-narrative-and-process` (§0–§4), `fundraising-instruments-dilution-terms-and-control` (§5–§9), `fundraising-diligence-valuation-and-exits` (§10–§13), `fundraising-public-markets-and-securities-regulation` (§14–§19), `fundraising-non-profit-donors-grants-and-metrics` (§20–§25). Section numbers are shared across the set; a reference written as §N → `skill` points into that sibling skill.
>
> **Currency:** Instruments, dilution mathematics and securities structure are stable. Two areas moved. See §26 below for the concentration of the private venture market and the US charitable deduction rewrite effective January 2026.

> **⚠️ Scope.** Complements a business reference (§4 financing overview, §12 negotiation)
> and an economics/accounting/tax reference (statements, entity structure, tax).
> **This is the deep version**, and it covers three worlds most treatments handle
> separately.
>
> ⚠️ **Not legal, tax or investment advice.** **Securities law is unforgiving and
> jurisdiction-specific — §19 → `fundraising-public-markets-and-securities-regulation` exists to tell you which questions to take to a lawyer.**
>
> **The three ideas that organize all of it:**
> 1. **⚠️ All fundraising sells the same thing: a claim on future value, in exchange for
>    capital now.** **Equity sells ownership, debt sells a promise, philanthropy sells
>    *participation in an outcome*.** ⚠️ **The instruments differ enormously; the
>    persuasion structure barely differs at all** (§2 → `fundraising-what-it-is-narrative-and-process`, §3 → `fundraising-what-it-is-narrative-and-process`).
> 2. **⚠️ Fundraising is a sales process with a long cycle, and treating it as anything
>    else is the most common failure.** **Pipeline, qualification, and the fact that most
>    "no"s are actually "not now" or "not me"** (§4 → `fundraising-what-it-is-narrative-and-process`).
> 3. **⚠️ The terms matter more than the amount, in every one of the three worlds.**
>    **Liquidation preference in private, covenants in public, restriction in
>    philanthropy.** ⚠️ **Money with the wrong strings attached has sunk more
>    organizations than insufficient money.**

---

## §26. What Moved — verified August 2026

### 26.1 ⚠️ Private venture: a bimodal market
**⚠️ Headline medians have become close to useless without splitting AI from non-AI, and
that's the single most important thing to know before benchmarking your own round.**

> **⚠️ GOTCHA — the reported medians disagree substantially, and I'm going to show you
> the spread rather than pick.** ⚠️ **For 2026 I found median seed round reported at
> $3.0M, ~$3.1M, ~$3.2M and $4.0M; median seed post-money at $20M, $24M and $24.3M;
> median Series A at $12M, $15M, $19.6M and $20M with post-money from $40M to $80M.**
> **Different datasets (Carta, PitchBook-NVCA, Crunchbase, AngelList) cover different
> populations and different windows.** ⚠️ **Carta's data covers startups using Carta for
> cap tables, which skews toward US venture-track software companies.** **Treat all of
> these as directional.**

**⚠️ What's consistent across sources:**
- **⚠️ Concentration is the whole story.** **AI took a reported ~50% of global venture
  funding in 2025, up from ~34% in 2024**, and **roughly 60% of 2025 capital went to
  just 629 companies raising $100M+.** ⚠️ **Mega-rounds at a handful of foundation-model
  companies absorb the majority; everyone else competes for what's left.**
- **⚠️ The AI premium is real and stage-dependent** — **reported at roughly 40%+ higher
  seed valuations, and at Series A AI companies reported near 2x the overall median.**
  **Non-AI B2B SaaS reportedly still prices around $14–16M pre-money at seed.**
- **⚠️ Dilution per round is stubbornly structural** — **seed reported at ~19–23%, Series
  A similar** — **because it's driven by the lead's ownership target** (§12 → `fundraising-diligence-valuation-and-exits`).
  **⚠️ Founders reaching Series B have commonly sold 35–40%** (§7 → `fundraising-instruments-dilution-terms-and-control`).
- **⚠️ The seed-to-Series-A graduation rate has fallen**, **reported from around ~50% to
  ~38%**, ⚠️ **and the timeline has stretched.** **One analysis describes a bimodal split:
  a fast track graduating in 14–15 months and a much larger "grind track" taking 22+
  months with a halved graduation rate.** **⚠️ The old "raise 18–24 months of runway"
  rule is no longer sufficient planning for the median company.**
- **⚠️ The bar for seed traction has risen** — **reported expectations around $300k–$500k
  ARR where a deck once sufficed.**
- **⚠️ Venture remains statistically rare.** **A commonly cited figure is that roughly
  0.05% of startups ever raise VC** — ⚠️ **the number is repeated across compilations
  more than it is sourced, so treat the precision sceptically while accepting the point:
  the overwhelming majority of businesses finance without it** (§5 → `fundraising-instruments-dilution-terms-and-control`).

### 26.2 ⚠️ US charitable deduction — rewritten, effective January 2026
**⚠️ This is the most significant change to US charitable deduction rules in roughly a
decade, it took effect 1 January 2026, and it is unusually well-attested — the sources
agree on every material point.** **It comes from the One Big Beautiful Bill Act, enacted
4 July 2025** (see an economics/accounting/tax reference §21.2 for OBBBA's business
provisions).

```
⚠️ NEW: 0.5% AGI FLOOR for itemizers (new IRC §170(b)(1)(I))
   Only giving ABOVE 0.5% of AGI is deductible. Applies to cash AND non-cash
   ⚠️ $200,000 AGI → first $1,000 of giving is not deductible
   ⚠️ $400,000 AGI → first $2,000 is not deductible
   Amounts below the floor generally carry forward up to five years

⚠️ NEW: UNIVERSAL ABOVE-THE-LINE DEDUCTION for non-itemizers
   Up to $1,000 single / $2,000 married filing jointly, for CASH gifts
   ⚠️ Reaches the large majority of taxpayers who don't itemize
   ⚠️ EXCLUDES donor-advised funds and most private foundations

⚠️ NEW: 1% FLOOR on corporate charitable deductions (of taxable income)

⚠️ NEW: 35% CAP on deduction value for top-bracket donors
   ⚠️ A donor in the 37% bracket now gets at most 35 cents per dollar

UNCHANGED / MADE PERMANENT: the 60% of AGI ceiling for cash gifts to public charities
```
> **⚠️ GOTCHA — the floor and the cap push in opposite directions on different donor
> segments, and a single undifferentiated fundraising strategy now serves neither.**
> ⚠️ **Small routine gifts from itemizers lose their tax benefit entirely** — **a board
> member giving $500 a year to the organization they serve may now get no deduction at
> all.** ⚠️ **Meanwhile millions of non-itemizers gain a deduction for the first time in
> years.** **The incentive structure shifted from concentrated toward broad
> participation at the bottom, while getting less generous at the top.**

**⚠️ The practical implications for fundraisers, which the sources broadly agree on:**
- **⚠️ Segment the file by likely itemization status** and **write different appeals for
  each.** **Lead with the universal deduction for non-itemizers; lead with bunching for
  itemizers.**
- **⚠️ "Bunching" becomes more important** — **concentrating several years of giving into
  one year to clear the floor** — **which means multi-year pledges with concentrated
  giving years, and a lumpier revenue pattern to plan around.**
- **⚠️ Appreciated securities and Qualified Charitable Distributions become relatively
  more attractive** — **QCDs from IRAs for donors 70½+ are not affected by the 0.5%
  floor at all.**
- **⚠️ Corporate partnerships need renegotiating** around the 1% floor, **and the
  corporate tax officer needs to be in the conversation.**
- **⚠️ Measure by donor count, average gift and channel mix rather than total revenue**,
  **because the structural change will move all three and total revenue will hide it.**

**⚠️ Caveats.** **This is US federal law only.** ⚠️ **Tax treatment is one input to giving
and generally not the dominant one — most donors give because they care, and the
literature on deduction elasticity is contested.** **Expect effects at the margin and in
timing rather than a wholesale collapse or boom.** ⚠️ **And this is orientation, not tax
advice** (§19 → `fundraising-public-markets-and-securities-regulation`'s framing applies).

---

## §27. Anti-Patterns

```
ALL THREE
⚠️ Pitching without mandate fit — most rejections are this (§2)
⚠️ A vague ask (§3)
⚠️ Chasing the slow no for months (§4)
⚠️ Raising reactively, in crisis, from a position of no leverage
⚠️ Concentration risk treated as a fundraising problem rather than governance (§20)

PRIVATE
⚠️ Stacking post-money SAFEs without modelling cumulative dilution (§6)
⚠️ Optimizing headline valuation over clean terms (§8)
⚠️ Accepting the "standard" option pool without a hiring plan (§7)
⚠️ Starting diligence unprepared and losing momentum (§11)
⚠️ Raising VC for a business that shouldn't (§5, and a business reference §4)

PUBLIC
⚠️ Going public to solve a problem an IPO doesn't solve (§14)
⚠️ Underestimating ongoing compliance cost and management time (§14)
⚠️ Debt covenants that bind exactly when performance dips (§10, §18)

NON-PROFIT
⚠️ Over-investing in corporate relative to individual (§20)
⚠️ Asking a major prospect too early (§21)
⚠️ Neglecting retention while funding acquisition (§21)
⚠️ Accepting reimbursement-based contracts without working capital (§22)
⚠️ Launching a public campaign without a lead gift (§23)
⚠️ Ignoring legacy giving because the payoff outlasts your tenure (§24)
⚠️ Managing to the overhead ratio (§25)
⚠️ Accepting restricted funding that doesn't cover its own true cost (§20, §25)
```

---

## §28. Misconceptions

| Misconception | Correction |
|---|---|
| Raising money means you succeeded | ⚠️ **It means you took on an obligation** (§1 → `fundraising-what-it-is-narrative-and-process`) |
| A good pitch overcomes a mandate mismatch | ⚠️ **It doesn't. Research mandate first** (§2 → `fundraising-what-it-is-narrative-and-process`) |
| Valuation is the term to negotiate | ⚠️ **Liquidation preference usually matters more** (§8 → `fundraising-instruments-dilution-terms-and-control`) |
| Early-stage valuation is an analysis | ⚠️ **It's raise size ÷ target ownership** (§12 → `fundraising-diligence-valuation-and-exits`) |
| A higher valuation is always better | ⚠️ **Not with structure attached** (§8 → `fundraising-instruments-dilution-terms-and-control`) |
| SAFEs are simple and low-stakes | ⚠️ **Post-money SAFEs stack dilution onto you** (§6 → `fundraising-instruments-dilution-terms-and-control`) |
| The option pool dilutes everyone | ⚠️ **Pre-money pools come out of founders** (§7 → `fundraising-instruments-dilution-terms-and-control`) |
| Dilution is bad | ⚠️ **Dilution that bought nothing is bad** (§7 → `fundraising-instruments-dilution-terms-and-control`) |
| Most startups raise VC | ⚠️ **A tiny fraction do** (§5 → `fundraising-instruments-dilution-terms-and-control`, §26.1) |
| Median round sizes tell you what to expect | ⚠️ **The market is bimodal — split AI/non-AI** (§26.1) |
| Debt is safer than equity | ⚠️ **The obligation survives bad quarters** (§10 → `fundraising-diligence-valuation-and-exits`) |
| An IPO is an exit | ⚠️ **It's a financing event with a lock-up** (§14 → `fundraising-public-markets-and-securities-regulation`, §15 → `fundraising-public-markets-and-securities-regulation`) |
| IPO pop means it went well | ⚠️ **Underpricing is money the company didn't get** (§15 → `fundraising-public-markets-and-securities-regulation`) |
| Exemption from registration means no rules | ⚠️ **Anti-fraud provisions always apply** (§19 → `fundraising-public-markets-and-securities-regulation`) |
| A demo day pitch is private | ⚠️ **It can be general solicitation** (§19 → `fundraising-public-markets-and-securities-regulation`) |
| Non-profits run on donations | ⚠️ **Earned revenue is the largest sector-wide source** (§20 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Corporate giving is a major source | ⚠️ **Individual giving dwarfs it** (§20 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Events are a revenue strategy | ⚠️ **Judge them as cultivation** (§24 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Winning a government contract is good news | ⚠️ **Reimbursement basis can break you** (§22 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Low overhead means an effective charity | ⚠️ **It often means an under-invested one** (§25 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Small gifts still get a tax deduction | ⚠️ **Not for itemizers below the 0.5% AGI floor from 2026** (§26.2) |
| Only itemizers get a charitable deduction | ⚠️ **Non-itemizers now get up to $1,000/$2,000** (§26.2) |

---

## §29. Numbers

```
PRIVATE (2026, ⚠️ reported ranges — see §26.1 on the disagreement)
Median seed round               ⚠️ $3.0M–$4.0M depending on source
Median seed post-money          ⚠️ $20M–$24.3M · non-AI B2B SaaS ~$14–16M pre
Median Series A                 ⚠️ $12M–$20M raised · $40M–$80M post
Dilution per priced round       ⚠️ ~20% (seed ~19–23%, A ~18–23%)
Founder ownership sold by B     ⚠️ ~35–40% before B dilutes further
Seed → Series A graduation      ⚠️ reported fallen from ~50% to ~38%
Seed → A timeline               ⚠️ 14–15 months fast track; 22+ months typical
AI share of global VC 2025      ⚠️ ~50% (from ~34% in 2024)
2025 capital to $100M+ rounds   ⚠️ ~60%, across 629 companies
Startups that ever raise VC     ⚠️ ~0.05% (widely cited, weakly sourced)
Prospects per close             ⚠️ 10–20x

PUBLIC
IPO lock-up                     commonly 90–180 days
IPO underpricing                ⚠️ persistent and well-documented
Capital structure priority      secured → senior → subordinated → preferred → common

NON-PROFIT (US, effective 1 Jan 2026)
⚠️ Itemizer floor                0.5% of AGI
⚠️ Non-itemizer deduction        $1,000 single / $2,000 MFJ, cash only, no DAFs
⚠️ Corporate floor               1% of taxable income
⚠️ Top-bracket deduction cap     35%
Cash gift ceiling               60% of AGI (now permanent)
Campaign quiet phase            ⚠️ 50–70% of goal before going public
Top gift in a campaign          ⚠️ often 10–20% of goal
Major gift cultivation          ⚠️ 12–24 months
Endowment spending policy       ~4–5% of rolling average
```

---

## §30. Books

| Author | Work | Why |
|---|---|---|
| **Feld & Mendelson** | ***Venture Deals*** | ⚠️ **§6–§9 → `fundraising-instruments-dilution-terms-and-control`. The single best book on private terms. Read before any term sheet** |
| **Kupor** | *Secrets of Sand Hill Road* | ⚠️ **How VCs think and why their incentives are what they are** |
| **Nesheim** | *High Tech Start Up* | Cap table mechanics |
| **Berkery** | *Raising Venture Capital for the Serious Entrepreneur* | Process depth |
| **Ritter (academic)** | IPO underpricing literature | ⚠️ **§15 → `fundraising-public-markets-and-securities-regulation`. Free online, and the data is the point** |
| **Panas** | ***Asking*** | ⚠️ **§21 → `fundraising-non-profit-donors-grants-and-metrics`. Short, and the best thing written on the major gift ask** |
| **Sargeant & Jay** | *Building Donor Loyalty* | ⚠️ **§21 → `fundraising-non-profit-donors-grants-and-metrics`'s retention evidence** |
| **Ahern & Joyaux** | *Keep Your Donors* | Retention and communication |
| **Klein** | *Fundraising for Social Change* | ⚠️ **Grassroots and small-org realistic** |
| **Fisher & Ury** | *Getting to Yes* | ⚠️ **Negotiation underpins all three parts** |

**Also**: **Giving USA** (annual US sector data), **AFP/Fundraising Effectiveness Project**
(retention data), **NVCA Yearbook** and **PitchBook-NVCA Venture Monitor** (private market
data), **Carta's State of Private Markets** (⚠️ **useful and platform-skewed — see
§26.1**), **and your regulator's own guidance for §19 → `fundraising-public-markets-and-securities-regulation`.**

---

## §31. Quick Reference

### 31.1 Picker
| Question | Where |
|---|---|
| Which instrument should I raise? | ⚠️ **What claim can you honestly offer?** (§1 → `fundraising-what-it-is-narrative-and-process`) |
| Why do so many funders say no? | ⚠️ **Mandate mismatch, usually** (§2 → `fundraising-what-it-is-narrative-and-process`) |
| How much should I ask for? | ⚠️ **Enough to hit a specific milestone** (§3 → `fundraising-what-it-is-narrative-and-process`) |
| They've gone quiet — what now? | ⚠️ **Force a decision. Treat silence as no** (§4 → `fundraising-what-it-is-narrative-and-process`) |
| SAFE or priced round? | ⚠️ **SAFE early, and model cumulative dilution** (§6 → `fundraising-instruments-dilution-terms-and-control`) |
| How much will I own after Series B? | ⚠️ **Commonly 60–65% sold. Model it** (§7 → `fundraising-instruments-dilution-terms-and-control`) |
| Which term matters most? | ⚠️ **Liquidation preference** (§8 → `fundraising-instruments-dilution-terms-and-control`) |
| Higher valuation or cleaner terms? | ⚠️ **Cleaner terms, nearly always** (§8 → `fundraising-instruments-dilution-terms-and-control`) |
| How do I raise my valuation? | ⚠️ **Competition, not argument** (§12 → `fundraising-diligence-valuation-and-exits`) |
| Can I advertise my raise? | ⚠️ **Not under 506(b). Ask a lawyer** (§19 → `fundraising-public-markets-and-securities-regulation`) |
| Where does non-profit money come from? | ⚠️ **Check YOUR mix — probably not where you think** (§20 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Biggest non-profit quick win? | ⚠️ **Retention, and monthly giving** (§21 → `fundraising-non-profit-donors-grants-and-metrics`, §24 → `fundraising-non-profit-donors-grants-and-metrics`) |
| When do I ask for the major gift? | ⚠️ **Later than feels comfortable** (§21 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Should we take this government contract? | ⚠️ **Model the reimbursement cash flow first** (§22 → `fundraising-non-profit-donors-grants-and-metrics`) |
| Are we ready for a campaign? | ⚠️ **Only with a credible lead gift** (§23 → `fundraising-non-profit-donors-grants-and-metrics`) |
| How do we prove we're efficient? | ⚠️ **Outcomes, not overhead ratio** (§25 → `fundraising-non-profit-donors-grants-and-metrics`) |

### 31.2 Before you sign / accept
- [ ] ⚠️ **Private: liquidation preference — 1x non-participating?** (§8 → `fundraising-instruments-dilution-terms-and-control`)
- [ ] ⚠️ **Private: option pool pre- or post-money, and sized to a real plan?** (§7 → `fundraising-instruments-dilution-terms-and-control`)
- [ ] Private: anti-dilution — weighted average, not full ratchet? (§8 → `fundraising-instruments-dilution-terms-and-control`)
- [ ] Private: board composition after this round? (§9 → `fundraising-instruments-dilution-terms-and-control`)
- [ ] Private: no-shop period — as short as possible? (§8 → `fundraising-instruments-dilution-terms-and-control`)
- [ ] ⚠️ **Debt: what covenants, and what happens in a bad quarter?** (§10 → `fundraising-diligence-valuation-and-exits`, §18 → `fundraising-public-markets-and-securities-regulation`)
- [ ] ⚠️ **Any raise: does my exemption actually cover how I've solicited?** (§19 → `fundraising-public-markets-and-securities-regulation`)
- [ ] ⚠️ **Non-profit: does this restricted gift cover its own true cost?** (§20 → `fundraising-non-profit-donors-grants-and-metrics`, §25 → `fundraising-non-profit-donors-grants-and-metrics`)
- [ ] ⚠️ **Non-profit: reimbursement basis — do we have the working capital?** (§22 → `fundraising-non-profit-donors-grants-and-metrics`)
- [ ] Non-profit: what reporting am I committing to, for how long? (§22 → `fundraising-non-profit-donors-grants-and-metrics`)

---

## §32. Method

**§1–§25 → `fundraising-what-it-is-narrative-and-process`, `fundraising-instruments-dilution-terms-and-control`, `fundraising-diligence-valuation-and-exits`, `fundraising-public-markets-and-securities-regulation`, `fundraising-non-profit-donors-grants-and-metrics` rest on stable material** — **instruments, dilution arithmetic, preference
mechanics, IPO process, the capital structure hierarchy, the donor pyramid and the major
gift cycle.** ⚠️ **None of it needed verification, and the worked examples in §7 → `fundraising-instruments-dilution-terms-and-control` and §8 → `fundraising-instruments-dilution-terms-and-control` are
arithmetic you can check yourself, which is why I included the numbers rather than
describing the concepts.**

**Two searches were run in August 2026**, on **private market benchmarks** and **the US
charitable deduction changes.**

**Confidence.** **High** in §1–§25 → `fundraising-what-it-is-narrative-and-process`, `fundraising-instruments-dilution-terms-and-control`, `fundraising-diligence-valuation-and-exits`, `fundraising-public-markets-and-securities-regulation`, `fundraising-non-profit-donors-grants-and-metrics`. ⚠️ **§8.1 → `fundraising-instruments-dilution-terms-and-control` is the section I'd most want read** — **the
liquidation preference worked example is the clearest way to see why a headline valuation
can be worth less than a lower one, and it's the term most often waved through.**
**§6 → `fundraising-instruments-dilution-terms-and-control`'s post-money SAFE gotcha is a close second, because it's a genuine change from the
older instrument that a lot of founder advice hasn't caught up with.**

⚠️ **§26.1 contains a disagreement I've deliberately shown rather than resolved.**
**Median seed round figures ranged across $3.0M/$3.1M/$3.2M/$4.0M and Series A across
$12M–$20M raised with $40M–$80M post-money, depending on source and window.** ⚠️ **Carta,
PitchBook-NVCA, Crunchbase and AngelList cover different populations — Carta's is
US-venture-track companies using Carta for cap tables, which is a real selection effect.**
**I've given ranges throughout rather than false precision.** **The structural claims —
extreme AI concentration, bimodal outcomes, ~20% dilution per round driven by ownership
targets, falling and slowing seed-to-A graduation — are consistent across every source and
are what actually affects planning.** ⚠️ **The "0.05% of startups raise VC" figure is
widely repeated and thinly sourced; I've flagged it as such.**

**⚠️ High confidence in §26.2, unusually so** — **the OBBBA charitable provisions were
consistent across every source I found, including law firms, accounting firms, a bank and
donor-advised-fund providers**: **0.5% AGI floor for itemizers, $1,000/$2,000
above-the-line for non-itemizers excluding DAFs, 1% corporate floor, 35% top-bracket cap,
60% AGI ceiling made permanent, all effective for tax year 2026.** ⚠️ **The one thing I'd
verify independently is the carryforward treatment of amounts below the floor** —
**sources describe five-year carryforward and one notes that pre-2026 carryforwards are
"likely" not subject to the floor "based on the statutory effective date," which is
hedged language doing real work.**

⚠️ **Sourcing caution across both.** **Private-market benchmark content is largely
published by cap-table platforms, data rooms and fundraising-service vendors with an
interest in you raising; charitable-deduction content is largely published by
donor-advised-fund providers, wealth managers and accounting firms with an interest in you
using their planning services.** **The underlying facts recur widely enough to be
reliable — and in §26.2 the tax provisions are statutory and checkable against IRC §170.**
⚠️ **The strategic advice wrapped around them is marketing, and I've tried to separate
the two.** **For anything with money attached, §19 → `fundraising-public-markets-and-securities-regulation`'s framing holds: this is orientation,
and the specifics belong with a lawyer or tax adviser.**